Trials / Conditions / Acute Myeloid Leukaemia (AML)

Acute Myeloid Leukaemia (AML)

19 registered clinical trials studyying Acute Myeloid Leukaemia (AML) — 11 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood- NCT07060001	The Methodist Hospital Research Institute	Phase 2
Recruiting	A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid NCT07148180	Jacqueline Garcia, MD	Phase 1 / Phase 2
Recruiting	A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies NCT07154823	Tempus AI	—
Not Yet Recruiting	RVU120 Rollover Study NCT06987058	Ryvu Therapeutics SA	Phase 2
Not Yet Recruiting	Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Mu NCT07264010	Nanfang Hospital, Southern Medical University	Phase 2 / Phase 3
Completed	AI-Assisted Acute Myeloid Leukemia Evaluation With the Leukemia End-to-End Analysis Platform (LEAP) Versus Cli NCT07203885	Harvard Medical School (HMS and HSDM)	N/A
Recruiting	Maintenance Venetoclax in AML Fit Patients NCT07244367	Sohag University	N/A
Not Yet Recruiting	NK Cell Infusion for Remission Consolidation in AML: A Phase II Trial NCT06783478	Hospital de Clinicas de Porto Alegre	Phase 2
Recruiting	L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induct NCT06788756	Moleculin Biotech, Inc.	Phase 2 / Phase 3
Recruiting	Safely Delivered Targeted High-dose Irradiation Followed by Adoptive Immunotherapy with Regulatory and Convent NCT06845592	University Of Perugia	N/A
Recruiting	Feasibility and Safety of Home Blood Count Measurement and Transfusions in Patients With Acute Myeloid Leukemi NCT07062250	Rigshospitalet, Denmark	N/A
Recruiting	Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics NCT05534620	medac GmbH	Phase 1
Completed	Mesenchymal Stem Cells in NPM1 Mutated Low Risk Acute Myeloid Leukemia: a Study of the Tumor Microenvironment NCT07379528	Fondazione IRCCS Policlinico San Matteo di Pavia	—
Active Not Recruiting	Safety and Efficacy of FT14 Conditioning for Allogeneic HSCT in Acute Myeloid Leukemia NCT07232953	Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia	Phase 2
Terminated	Panobinostat Maintenance After HSCT fo High-risk AML and MDS NCT04326764	Goethe University	Phase 3
Completed	Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic NCT02979366	Institut de Recherches Internationales Servier	Phase 1
Completed	A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients NCT02550535	Cell Medica Ltd	Phase 1 / Phase 2
Completed	Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysp NCT02920541	Institut de Recherches Internationales Servier	Phase 1
Completed	A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), Wi NCT01488565	Peter MacCallum Cancer Centre, Australia	Phase 2